Dr. Anthony Stein, MD
Hematology (Hematology (Internal Medicine) Physician)
1500 E Duarte Rd
Duarte, CA 91010
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 48
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 129
Licensed in California since 1984, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
CA license A41452 (first issued 1984; current) -
Hematology & Oncology Physician
CA license A41452 (first issued 1984; current) -
Internal Medicine Physician
CA license A41452 (first issued 1984; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- City of Hope Medical Foundation (982 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 129
- Services billed
- 848
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 353 | 76 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 224 | 34 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 33 | 13 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 28 | 11 |
| Established patient office or other outpatient visit, 40-54 minutes | 26 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 28 |
| Acyclovir Other prescribers in Duarte, CA | 22 |
| Sirolimus | 17 |
| Pantoprazole Sodium Other prescribers in Duarte, CA | 15 |
| Escitalopram Oxalate Other prescribers in Duarte, CA | 13 |
| Cresemba (isavuconazonium sulfate) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 26 payments worth $16,627 in total to this clinician.
| AbbVie Inc. | $14,438 |
|---|---|
| Syndax Pharmaceuticals, Inc. | $2,135 |
| Novartis Pharmaceuticals Corporation | $28.06 |
| Rigel Pharmaceuticals, Inc. | $25.54 |
| Consulting Fee | $13,129 |
|---|---|
| Travel and Lodging | $2,894 |
| Food and Beverage | $595 |
| Education | $9.65 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Mar 27, 2025 | Consulting Fee | $3,563 |
| AbbVie Inc. Dec 22, 2025 | Consulting Fee | $2,731 |
| Syndax Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,085 |
| AbbVie Inc. Mar 27, 2025 | Consulting Fee | $1,900 |
| AbbVie Inc. Feb 21, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $1,533 |
| AbbVie Inc. Dec 22, 2025 | Consulting Fee | $1,425 |
| AbbVie Inc. Dec 22, 2025 | Consulting Fee | $1,425 |
| AbbVie Inc. Nov 13, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $606 |
| AbbVie Inc. Nov 12, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $326 |
| AbbVie Inc. Feb 19, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $214 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 22, 2025 | Consulting Fee | $2,731 |
| AbbVie Inc. Dec 22, 2025 | Consulting Fee | $1,425 |
| AbbVie Inc. Dec 22, 2025 | Consulting Fee | $1,425 |
| Syndax Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,085 |
| AbbVie Inc. Nov 13, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $606 |
| AbbVie Inc. Nov 12, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $326 |
| AbbVie Inc. Jul 17, 2025 | Education EPKINLY · ONCOLOGY · in-kind | $9.65 |
| AbbVie Inc. Mar 27, 2025 | Consulting Fee | $3,563 |
| AbbVie Inc. Mar 27, 2025 | Consulting Fee | $1,900 |
| AbbVie Inc. Feb 21, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $1,533 |
| AbbVie Inc. Feb 20, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $214 |
| AbbVie Inc. Feb 19, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $214 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $939,427 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
Sanofi US Services Inc. · Terminated · NCT06508489 - A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Ac…
Amgen Inc. - First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sanofi US Services Inc. · Terminated · NCT05086315 - A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Comple…
Amgen Inc. - Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT06068868 - A phase i, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-120 in subjects with advanced hematologic malignancies…
Servier Pharmaceuticals LLC - A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acut…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.